GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,800 ($23.50) price objective by equities research analysts at Citigroup Inc. in a report released on Thursday. The firm currently has a a “buy” rating on the stock. Citigroup Inc.’s price target points to a potential upside of 9.56% from the stock’s previous close.
A number of other brokerages also recently commented on GSK. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Tuesday, August 2nd. Jefferies Group reiterated a “buy” rating and set a GBX 2,000 ($26.11) price objective on shares of GlaxoSmithKline plc in a research report on Friday, July 29th. BNP Paribas reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 29th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Thursday, July 28th. Finally, Deutsche Bank AG reissued a “hold” rating and set a GBX 1,700 ($22.19) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 28th. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have issued a buy rating to the stock. GlaxoSmithKline plc currently has a consensus rating of “Hold” and an average target price of GBX 1,676.44 ($21.88).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1666.00 on Thursday. The stock’s market capitalization is GBX 80.98 billion. The company’s 50 day moving average price is GBX 1,645.84 and its 200-day moving average price is GBX 1,542.41. GlaxoSmithKline plc has a 52 week low of GBX 1,261.50 and a 52 week high of GBX 1,716.50.
The company also recently declared a dividend, which will be paid on Thursday, October 13th. Investors of record on Thursday, August 11th will be issued a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.12%. The ex-dividend date is Thursday, August 11th.
In related news, insider Witty,Sir Andrew P sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43). Also, insider Slaoui,Moncef purchased 28 shares of the stock in a transaction that occurred on Friday, August 12th. The stock was purchased at an average price of GBX 2,208 ($28.82) per share, for a total transaction of £618.24 ($807.00).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.